Sonja Althammer, PhD | Authors


Sonja Althammer Discusses Biomarkers for Durvalumab in Lung Cancer

November 13, 2016

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, discusses a study looking to define a subgroup of patients with non–small cell lung cancer who respond best to treatment with the PD-L1 inhibitor durvalumab.